Associated Papers
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Kuras M et al.
Cancers, 2025
ACE Phenotyping in Human Blood and Tissues: Revelation of ACE Outliers and Sex Differences in ACE Sialylation.
Enyedi EE et al.
Biomedicines, 2024
The Association of PLA2G7 Gene Polymorphisms with Serum Lp-PLA2 Activity and Lipid Profile in Han Chinese Patients with Coronary Heart Disease.
Wang Y et al.
Pharmacogenomics and Personalized Medicine, 2024
Indicators of HSV1 Infection, ECM-Receptor Interaction, and Chromatin Modulation in a Nuclear Family with Schizophrenia.
Huang YC et al.
Journal of Personalized Medicine, 2023
Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease.
Ma S et al.
Disease Markers, 2022
Case report: Whole-exome sequencing identifies a novel DES mutation (p. E434K) in a Chinese family with cardiomyopathy and sudden cardiac death.
Liu YX et al.
Frontiers in Cardiovascular Medicine, 2022
Case report: Two unique nonsense mutations in HTRA1-related cerebral small vessel disease in a Chinese population and literature review.
Chen W et al.
Frontiers in Neurology, 2022
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge.
Brancaccio M et al.
Diagnostics (basel, Switzerland), 2021
Human Secretary Phospholipase A2 Mutations and Their Clinical Implications.
Khan MI et al.
Journal of Inflammation Research, 2020
Introducing the first whole genomes of nationals from the United Arab Emirates.
AlSafar HS et al.
Scientific Reports, 2019
Identifying individual risk rare variants using protein structure guided local tests (POINT).
Marceau West R et al.
Plos Computational Biology, 2019
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Gregson JM et al.
European Journal of Preventive Cardiology, 2017
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A et al.
Plos One, 2017
A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.
Qi Y et al.
Scientific Reports, 2016
Kuwaiti population subgroup of nomadic Bedouin ancestry-Whole genome sequence and analysis.
John SE et al.
Genomics Data, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
Grallert H et al.
European Heart Journal, 2012
Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes.
Postula M et al.
Journal of Thrombosis and Haemostasis : Jth, 2011
Two new highly polymorphic markers in the 3' UTR region of the PLA2G7 gene.
Gomez Lira M et al.
International Journal of Immunogenetics, 2007
Investigation of genes coding for inflammatory components in Parkinson's disease.
Håkansson A et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2005
Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease.
Ninio E et al.
Human Molecular Genetics, 2004
The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity.
Kakafika AI et al.
Journal of Lipid Research, 2003
Lack of evidence for associations between plasma platelet-activating factor acetylhydrolase deficiency and schizophrenia.
Ohtsuki T et al.
Psychiatry Research, 2002
Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia.
Bell R et al.
Biochemical and Biophysical Research Communications, 1997